Company / Return on Equity (ROE)
Voyager Therapeutics, Inc. Return on Equity (ROE) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
44.1%
FY2025
5-year range
-78.6% / 44.1%
FY2021-FY2025
Trend
+156.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Equity (ROE) returned to growth in FY2025 after 2 years of decline, reaching 44.1%.
Based on SEC 10-K filings.
44.1% in FY2025 with a 5-year CAGR of +234.2%.
Improved from -74.9% to 44.1% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +20.3pp
- 5-Year Change
- +234.2pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 156.1% year-over-year.
- Lowest return on equity (roe) in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.34 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 44.1% | +156.1% |
| FY2024 | -78.6% | -5.0% |
| FY2023 | -74.9% | -414.6% |
| FY2022 | 23.8% | +154.3% |
| FY2021 | -43.8% | +77.0% |
| FY2020 | -190.1% | -260.4% |
| FY2019 | -52.7% | -78.4% |
| FY2018 | -29.6% | -68.5% |
| FY2017 | -17.5% | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026